Make your own free website on
Provigil (a.k.a. Modafinil in other countries)

The drug Modafinil finally reachs the shores of the United States

Information as well as links provided to further explore this, the first new medication and possibly the most effective new treatment for sufferers of sleep disorders in over 20 years.

Provigil, the long awaited new drug for the treatment of EDS, and Narcolepsy will finally make its long awaited introduction to sufferers of not only these sleep disorders. But also many others as well. Conditions, and perhapes after it's safety is further agreed on, possibly to the general public as a stimulant for ocassional usage.

For a article explaining further what Provigil is and who provides it in so much as it's pharma patent holders etc choose
the link provided "here".

Provigil (Modafinil) & it's makers;

           Cephalon, Inc.
            145 Brandywine Parkway
            West Chester, PA 19380
            Phone: (610) 344-0200
            Fax: (610)-344-0065
            Contact Person: Jason Rubin, VP, Corporate Communications
-           610-738-6302

          About Cephalon, Inc.

           Founded in 1987, Cephalon, Inc. is an international
           biopharmaceutical company dedicated to the discovery,
           development and marketing of innovative products to treat
           neurological disorders and cancer. The company is
           committed to providing patients and the medical community
           with treatment options for diseases where few or no
          adequate therapies currently exist.

           Headquartered in West Chester, Pennsylvania, Cephalon
           currently employs approximately 300 people in the United
           States and Europe. The company's European headquarters,
           Cephalon U.K. Ltd., is located in Guildford, England and
           supports offices in France, Germany and The Benelux
           (Belgium, Luxemburg and The Netherlands).

           The company's research and development efforts focus
           primarily on neurodegenerative disorders, which are
           characterized by the death of neurons, the specialized
           conducting cells of the nervous system. The company utilizes
           its technical expertise in molecular biology, molecular
           pharmacology, biochemistry, cell biology and chemistry to
           develope products in four core technology areas:

           neurotrophic factors, protease inhibitors, signal transduction
           modulators and gene transcription regulators. In addition,
           Cephalon has been a leader in the development of transgenic
           and gene-targeted animal models. Cephalon believes that its
           multidisciplinary technology approach facilitates the
           development of a portfolio of potential products for the
           treatment of neurological disorders such as narcolepsy,
           amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease),
           multiple sclerosis, peripheral neuropathies, Alzheimer's
           disease and stroke. Certain aspects of this technology have
           also allowed Cephalon to diversify its therapeutic objectives to
           include novel approaches for the treatment of cancer,
           especially prostate cancer.

           The company has established sales organizations in the
           United States, the United Kingdom and France focused on
           neurologists and certain other specialists. In the United
           States, the company is co-promoting two Bristol-Myers
           Squibb proprietary products, Stadol NS® (butorphanol
           tartrate), and Serzone® (nefazodone hydrochloride), as well
           as Intrathecal Baclofen Therapy (ITB™), a product of
           Medtronic Inc. These products are trademarks of Bristol
           Myers Squibb and Medtronic, Inc., respectively. In the
           United Kingdom, the company is marketing PROVIGIL®
           (modafinil) tablets. Under an exclusive sales and marketing
           agreement with Laboratoire Aguettant S.A., the company
           is marketing Apokinon® (apomorphine hydrochloride) in

           A new drug application (NDA) has been filed and is pending
           with the U.S. Food and Drug Administration (FDA) for the use
           of PROVIGIL in treating the excessive daytime sleepiness
           associated with narcolepsy. In May 1998, the company
           received authorization to market PROVIGIL in the Republic of
           Ireland, and launch is planned following regulatory clearance
           of U.S. manufacturing arrangements. The company and
          Chiron Corporation have filed an NDA, which is currently under
          review with the FDA for the use of MYOTROPHIN®
          (mecasermin) Injection in the treatment of ALS. Cephalon and
          Chiron are currently providing MYOTROPHIN Injection to a
          limited number of patients with ALS in the United States under
          a treatment investigation new drug (T-IND) protocol
          (MYOTROPHIN Expanded Access Program), which allows
          limited distribution of this unapproved drug.

Further reading provided at:

"Cephalon Inc. Talks about Narcolepsy"

" Common Recommendations for Behavioral Therapy "
   View the Movie here at these links....
            A) View a QuickTime Movie (290 KB)
            B) View an AVI using Netscape (1465 KB)
            C) View an AVI using MSIE (1465 KB)

For more information about EDS and to receive brochures about EDS and related sleep disorders, call toll-free EDS info line at: 1-800-41-AWAKE

American Sleep Disorders Association

National Sleep Foundation

Narcolepsy Network

[the] Sleep Medicine Home Page

Excessive Daytime Sleepiness (EDS) (web site)

Sleep Disorders


May 98 - Provigil Approved In Republic Of Ireland For Narcolepsy
Mar-98 - Provigil Launched In U.K. For Narcolepsy

Philadelphia Business Journal - Feb 9th 1998
            " FDA nears OK on narcolepsy drug "

New Drug Info (web site)'s Provigil Update

Cephalon Inc., Research & Developement (Provigil)

Narcolepsy & Importing (main web site)

Hoover's Company Profiles (Cephalon Inc.)

Health Touch - Article - " Living with Narcolepsy "

Provigil talked about on Internet News Group Forums:

98/09/16 020 Re: narcolepsy and meds

98/09/25 019 Re: Exessive Daytime Sleepni

98/08/31 018 Re: Provigil

Articles on my web site you might find interesting:

" Modafinil - A new drug being developed by Cephalon, Inc. for
treatment of narcolepsy "

Fatigue & Modafinil (Provigil)

" Modafinil: is it the Ultimate Stimulant? "

Back to Introduction Page